182 related articles for article (PubMed ID: 21674241)
1. BMP-4 expression has prognostic significance in advanced serous ovarian carcinoma and is affected by cisplatin in OVCAR-3 cells.
Laatio L; Myllynen P; Serpi R; Rysä J; Ilves M; Lappi-Blanco E; Ruskoaho H; Vähäkangas K; Puistola U
Tumour Biol; 2011 Oct; 32(5):985-95. PubMed ID: 21674241
[TBL] [Abstract][Full Text] [Related]
2. Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin.
Soyama H; Miyamoto M; Takano M; Aoyama T; Matsuura H; Sakamoto T; Takasaki K; Kuwahara M; Kato K; Yoshikawa T; Iwahashi H; Tsuda H; Furuya K
Med Oncol; 2017 Nov; 34(12):201. PubMed ID: 29168038
[TBL] [Abstract][Full Text] [Related]
3. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.
Alvarez AA; Axelrod JR; Whitaker RS; Isner PD; Bentley RC; Dodge RK; Rodriguez GC
Gynecol Oncol; 2001 Aug; 82(2):273-8. PubMed ID: 11531279
[TBL] [Abstract][Full Text] [Related]
4. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer.
Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A
Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary.
Itamochi H; Kigawa J; Akeshima R; Sato S; Kamazawa S; Takahashi M; Kanamori Y; Suzuki M; Ohwada M; Terakawa N
Oncology; 2002; 62(4):349-53. PubMed ID: 12138243
[TBL] [Abstract][Full Text] [Related]
7. Thrombospondin-1 and -2 messenger RNA expression in epithelial ovarian tumor.
Kodama J; Hashimoto I; Seki N; Hongo A; Yoshinouchi M; Okuda H; Kudo T
Anticancer Res; 2001; 21(4B):2983-7. PubMed ID: 11712798
[TBL] [Abstract][Full Text] [Related]
8. Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status.
Bock AJ; Tuft Stavnes H; Kærn J; Berner A; Staff AC; Davidson B
Tumour Biol; 2011 Jun; 32(3):589-96. PubMed ID: 21350924
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma.
Siamakpour-Reihani S; Owzar K; Jiang C; Turner T; Deng Y; Bean SM; Horton JK; Berchuck A; Marks JR; Dewhirst MW; Alvarez Secord A
Gynecol Oncol; 2015 Oct; 139(1):23-9. PubMed ID: 26260910
[TBL] [Abstract][Full Text] [Related]
10. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.
Rubatt JM; Darcy KM; Hutson A; Bean SM; Havrilesky LJ; Grace LA; Berchuck A; Secord AA
Gynecol Oncol; 2009 Mar; 112(3):469-74. PubMed ID: 19135712
[TBL] [Abstract][Full Text] [Related]
11. FGF18 as a potential biomarker in serous and mucinous ovarian tumors.
El-Gendi S; Abdelzaher E; Mostafa MF; Sheasha GA
Tumour Biol; 2016 Mar; 37(3):3173-83. PubMed ID: 26427667
[TBL] [Abstract][Full Text] [Related]
12. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions.
Davidson B; Reich R; Kopolovic J; Berner A; Nesland JM; Kristensen GB; Tropé CG; Bryne M; Risberg B; van de Putte G; Goldberg I
Clin Exp Metastasis; 2002; 19(2):135-44. PubMed ID: 11964077
[TBL] [Abstract][Full Text] [Related]
14. Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion.
Davidson B; Smith Y; Nesland JM; Kærn J; Reich R; Tropè CG
Hum Pathol; 2013 Nov; 44(11):2449-60. PubMed ID: 24011953
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway.
Bai L; Wang A; Zhang Y; Xu X; Zhang X
Exp Cell Res; 2018 May; 366(2):161-171. PubMed ID: 29548748
[TBL] [Abstract][Full Text] [Related]
16. Influence of gonadotropin-releasing hormone agonist on the effect of chemotherapy upon ovarian cancer and the prevention of chemotherapy-induced ovarian damage: an experimental study with nu/nu athymic mice.
Lin QY; Wang YF; Weng HN; Sheng XJ; Jiang QP; Yang ZY
J Zhejiang Univ Sci B; 2012 Nov; 13(11):894-903. PubMed ID: 23125082
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
18. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
Liu G; Yang D; Rupaimoole R; Pecot CV; Sun Y; Mangala LS; Li X; Ji P; Cogdell D; Hu L; Wang Y; Rodriguez-Aguayo C; Lopez-Berestein G; Shmulevich I; De Cecco L; Chen K; Mezzanzanica D; Xue F; Sood AK; Zhang W
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25995442
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implications of histological tumor regression (Böhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.
Rajkumar S; Polson A; Nath R; Lane G; Sayasneh A; Jakes A; Begum S; Mehra G
Gynecol Oncol; 2018 Nov; 151(2):264-268. PubMed ID: 30197060
[TBL] [Abstract][Full Text] [Related]
20. Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer.
De Stefano I; Zannoni GF; Prisco MG; Fagotti A; Tortorella L; Vizzielli G; Mencaglia L; Scambia G; Gallo D
Gynecol Oncol; 2011 Sep; 122(3):573-9. PubMed ID: 21665249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
